Bleomycin and the skin

British Journal of Dermatology

Volumn 155, Issue 5, 2006, Pages 869-875

  Yamamoto, T ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Adverse effects; Bleomycin; Skin

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; DACARBAZINE; ETOPOSIDE; PEPLEOMYCIN; VINCRISTINE;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; AGE; ALOPECIA; BONE MARROW TOXICITY; DERMATITIS; DRUG CYTOTOXICITY; DRUG INDICATION; ERYTHEMA; GANGRENE; HIDRADENITIS; HUMAN; HYPERPIGMENTATION; HYPERTROPHIC SCAR; KELOID; LUNG FIBROSIS; LUNG TOXICITY; NAIL DISEASE; NEUTROPHILIC ECCRINE HIDRADENITIS; NONHUMAN; PRIORITY JOURNAL; PRURITUS; PUSTULOSIS; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SKIN CANCER; SKIN EDEMA; SKIN NECROSIS; SKIN NODULE; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; SYSTEMIC SCLEROSIS; VERRUCA VULGARIS;

ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; DERMATOLOGIC AGENTS; DRUG ERUPTIONS; HUMANS; RISK FACTORS; SKIN DISEASES;

EID: 33749831218     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07474.x     Document Type: Review

References (108)

1. Umezawa H, Maeda K, Takeuchi T, Okami Y. New antibiotics, bleomycin A and B. J Antibiot 1966; 19:200-9.
2. Onuma T, Holland JF, Masuda H et al. Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer 1974; 22:1230-8.
3. Takeda A, Nonaka M, Ishikawa A, Higuchi D. Immunohistochemical localization of the neutral cysteine protease bleomycin hydrolase in human skin. Arch Dermatol Res 1999; 291:238-40.
4. Cohen IS, Mosher MB, O'Keefe EJ et al. Cutaneous toxicity of bleomycin in therapy. Arch Dermatol 1973; 107:553-5.
5. Dantzig PI. Immunosuppressive and cytotoxic drugs in dermatology. Arch Dermatol 1974; 110:393-406.
6. Werner Y, Törnberg B. Cutaneous side effects of bleomycin therapy. Acta Derm Venereol (Stockh) 1976; 56:155-8.
7. Nixon DW, Pirozzi D, York RM. Dermatologic changes after systemic cancer therapy. Cutis 1981; 27:181-94.
8. DeSpain JD. Dermatologic toxicity of chemotherapy. Semin Oncol 1992; 19:501-7.
9. Remlinger KA. Cutaneous reactions to chemotherapy drugs. The art of consultation. Arch Dermatol 2003; 139:77-81.
10. Barlogie B, Drewinko B, Schumann J, Freireich EJ. Pulse cytophotometric analysis of cell cycle perturbation with bleomycin in vitro. Cancer Res 1976; 36:1182-7.
11. Noda A. Gene expression in ataxia telangiectasia cells as perturbed by bleomycin treatment. Somat Cell Mol Genet 1992; 18:113-22.
12. Kuo MT, Auger LT, Saunders GF, Haidle CW. Effect of bleomycin on the synthesis and function of RNA. Cancer Res 1977; 37:1345-8.
13. Burger RM, Peisach J, Horwitz SB. Activated bleomycin: a transient complex of drug, iron and oxygen that degradates DNA. J Biol Chem 1981; 256:11636-44.
14. Takeuchi T. Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry. J Cancer Res Clin Oncol 1995; 121:505-10.
15. Tounekti O, Pron G, Belehradek J Jr, Mir LM. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 1993; 53:5462-9.
16. Hamilton RF Jr, Li L, Felder TB, Holian A. Bleomycin induces apoptosis in human alveolar macrophages. Am J Physiol 1995; 269:L318-25.
17. Muller M, Strand S, Hug H et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99:403-13.
18. Ramp U, Dejosez M, Mahotka C et al. Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma. Br J Cancer 2000; 82:1851-9.
19. Kato M, Iotani N, Suzuki T et al. Mechanism of anti-tumor effect of combination of bleomycin and shock waves. Jpn J Cancer Res 2000; 91:1065-72.
20. Mekid H, Tounekti O, Spatz A et al. In vivo evolution of tumour cells after the generation of double-strand DNA breaks. Br J Cancer 2003; 88:1763-71.
21. Sadek H, Azli N, Wendling JL et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil and bleomycin. Cancer 1990; 66:1692-6.
22. Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol 1999; 22:32-4.
23. Blum B, Carter SK, Agre K. A clinical review of bleomycin: a new antineoplastic agent. Cancer 1973; 31:903-14.
24. Heller R, Jaroszeski M, Reintgen DS et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998; 83:148-57.
25. Mir LM, Glass LF, Sersa G et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1988; 77:2336-42.
26. Shumer SM, O'Keefe EJ. Bleomycin in the treatment of recalcitrant warts. J Am Acad Dermatol 1983; 9:91-6.
27. Amer M, Diab N, Ramadan A et al. Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant warts. J Am Acad Dermatol 1988; 18:1313-16.
28. Shelley WB, Shelley D. Intralesional bleomycin sulfate therapy for warts. A novel bifurcated needle puncture technique. Arch Dermatol 1991; 127:234-6.
29. Munn SE, Higgins E, Marshall M, Clement M. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Br J Dermatol 1996; 135:969-71.
30. Templeton SF, Solomon AR, Swerlick RA. Intradermal bleomycin injections into normal human skin: a histopathologic and immunopathologic study. Arch Dermatol 1994; 130:577-83.
31. James MP, Collier PM, Aherne W et al. Histologic, pharmacologic, and immunocytochemical effects of injection of bleomycin into viral warts. J Am Acad Dermatol 1993; 28:933-7.
32. Espana A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg 2001; 27:23-7.
33. Kawai K, Akaza H. Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer. Expert Opin Drug Saf 2003; 2:587-96.
34. Cooper KR, Hong WK. Prospective study of the pulmonary toxicity of continuously infused bleomycin. Cancer Treat Rep 1981; 65:419-25.
35. Carlson RW, Sikic BJ. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983; 99:823-33.
36. Yagoda A, Mukherji B, Young C et al. Bleomycin, an antitumor antibiotic: clinical experience in 274 patients. Ann Intern Med 1972; 77:861-70.
37. Samuels ML, Johnson DE, Holoye PY, Lanzotti VJ. Large-dose bleomycin therapy and pulmonary toxicity: a possible role of prior radiotherapy. JAMA 1976; 235:1117-20.
38. D'Cruz D. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol Lett 2000; 112-113:421-32.
39. Abess A, Keel DM, Graham BS. Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol 2003; 139:337-9.
40. Fernandez-Obregon AC, Hogan KP, Bibro MK. Flagellate pigmentation from intrapleural bleomycin. A light microscopy and electron microscopy study. J Am Acad Dermatol 1985; 13:464-8.
41. Polla BS, Merot Y, Saurat JH, Slosman D. Flagellate pigmentation from bleomycin. J Am Acad Dermatol 1986; 14:690 (Letter).
42. Guillet G, Guillet MH, de Meaux H et al. Cutaneous pigmented stripes and bleomycin treatment. Arch Dermatol 1986; 122:381-2.
43. Lindae ML, Hu CH, Nickoloff BJ. Pruritic erythematous linear plaques on the neck and back. Arch Dermatol 1987; 123:393-8.
44. Rademaker M, Meyrick-Thomas RH, Lowe DG. Linear streaking due to bleomycin. Clin Exp Dermatol 1987; 12:457-9.
45. Lazar AP, Lazar P. Streaky pigmentation in a patient with acquired immune deficiency syndrome (AIDS). Cutis 1988; 42:397-8.
46. Vignini M, Miori L, Brusamoliono E, Pelfini C. Linear streaking after bleomycin administration. Clin Exp Dermatol 1989; 14:261 (Letter).
47. Cortina P, Garrido JA, Tomas JF et al. 'Flagellate' erythema from bleomycin. Dermatologica 1990; 180:106-9.
48. Miori L, Vignini M, Rabbiosi G. Flagellate dermatitis after bleomycin: a histological and immunohistochemical study. Am J Dermatopathol 1990; 12:598-602.
49. Duhra P, Ilchyshyn A, Das RN. Bleomycin-induced flagellate erythema. Clin Exp Dermatol 1991; 16:216-17.
50. Tsuji T, Sawabe M. Hyperpigmentation in striae distensae after bleomycin treatment. J Am Acad Dermatol 1993; 28:503-5.
51. Mowad CM, Nguyen TV, Elenitsas R, Leyden JJ. Bleomycin-induced flagellate dermatitis: a clinical and histopathological review. Br J Dermatol 1994; 131:700-2.
52. Zaki I, Haslam P, Scerri L. Flagellate erythema after intraperitoneal bleomycin. Clin Exp Dermatol 1994; 19:366-7.
53. Mullai N, Khokha N, Shimoto G. Bleomycin cutaneous toxicity. J Clin Oncol 1998; 16:1625-7.
54. Yamamoto T, Yokozeki H, Nishioka K. Dermal sclerosis in the lesional skin of 'flagellate' erythema (scratch dermatitis) induced by bleomycin. Dermatology 1998; 297:399-400.
55. Rubeiz NG, Salem Z, Dibbs R, Kibbi A-G. Bleomycin-induced urticarial flagellate drug hypersensitivity reaction. Int J Dermatol 1999; 38:140-1.
56. Nigro MG, Hsu S. Bleomycin-induced flagellate pigmentation. Cutis 2001; 68:285-6.
57. von Hilsheimer GE, Norton SA. Delayed bleomycin-induced hyperpigmentation and pressure on the skin. J Am Acad Dermatol 2002; 46:642-3.
58. Wright AL, Bleehen SS, Champion AE. Reticulate pigmentation due to bleomycin: light- and electron-microscopic studies. Dermatologica 1990; 180:255-7.
59. Kukla LJ, McGuire WP. Heat-induced recall of bleomycin skin changes. Cancer 1982; 50:2283-4.
60. Braun J, Hahn GM. Enhanced cell killing by bleomycin and 43°C hyperthermia and the inhibition of recovery from potentially lethal damage. Cancer Res 1975; 35:2921-7.
61. Hladunewich M, Sawka C, Fam A, Franssen E. Raynaud's phenomenon and digital gangrene as a consequence of treatment for Kaposi's sarcoma. J Rheumatol 1997; 24:2371-5.
62. Reiser M, Bruns C, Hartmann P et al. Raynaud's phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi's sarcoma. Eur J Clin Microbiol Infect Dis 1998; 17:58-60.
63. Fertakos RJ, Mintzer DM. Digital gangrene following chemotherapy for AIDS-related Kaposi's sarcoma. Am J Med 1992; 93:581-2.
64. Elomaa I, Pajunen M, Virkkunen P. Raynaud's phenomenon progressing to gangrene after vincristine and bleomycin therapy. Acta Med Scand 1984; 216:323-6.
65. Vayssairat M, Gaitz JP, Bamberger N. Digital gangrene, HIV infection and bleomycin treatment. J Rheumatol 1993; 20:921 (Letter).
66. Snauwaert J, Degreef H. Bleomycin-induced Raynaud's phenomenon and acral sclerosis. Dermatologica 1984; 169:172-4.
67. Epstein E. Intralesional bleomycin and Raynaud's phenomenon. J Am Acad Dermatol 1991; 24:785-6.
68. Gregg LJ. Intralesional bleomycin and Raynaud's phenomenon. J Am Acad Dermatol 1992; 27:279-80.
69. de Pablo P, Aguillar A, Gallego MA. Raynaud's phenomenon and intralesional bleomycin. Acta Derm Venereol (Stockh) 1992; 72:465 (Letter).
70. Vanhooteghem O, Richert B, de la Brassinne M. Raynaud phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin. Pediatr Dermatol 2001; 18:249-51.
71. Caumes E, Guermonprez G, Katlama C, Gentilini M. AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin. AIDS 1992; 6:1483-7.
72. Gill PS, Rarick M, McCutchan JA et al. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991; 90:427-33.
73. Bellmunt J, Navarro M, Morales S et al. Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity. Cancer 1990; 65:303-9.
74. Correia O, Ribas F, Azevedo R et al. Gangrene of the fingertips after bleomycin and methotrexate. Cutis 2000; 66:271-4.
75. Surville-Barland J, Caumes E, Ankri A et al. Bleomycin-induced digital gangrene. Eur J Dermatol 1998; 8:221 (Letter).
76. Wakefield PE, James WD, Samlaska CP, Meltzer MS. Tumor necrosis factor. J Am Acad Dermatol 1991; 24:675-85.
77. Finch WR, Rodnan GP, Buckingham RB et al. Bleomycin-induced scleroderma. J Rheumatol 1980; 7:651-9.
78. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol 1992; 19:294-6.
79. Kim K-H, Yoon T-J, Oh C-W et al. A case of bleomycin-induced scleroderma. J Korean Med Sci 1996; 11:454-6.
80. Passiu G, Cauli A, Atzeni F et al. Bleomycin-induced scleroderma: report of a case with a chronic course rather than the typical acute/subacute self-limiting form. Clin Rheumatol 1999; 18:422-4.
81. Mountz JD, Downs Minor MB, Turner R et al. Bleomycin-induced cutaneous toxicity in the rat: analysis of histopathology and ultrastructure compared with progressive systemic sclerosis (scleroderma). Br J Dermatol 1983; 108:679-86.
82. Yamamoto T, Takagawa S, Katayama I et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112:456-62.
83. Yamamoto T. Animal model of sclerotic skin induced by bleomycin: a clue to the pathogenesis of and therapy for scleroderma? Clin Immunol 2002; 102:209-16.
84. Beutner KR, Packman CH, Markowitch W. Neutrophilic eccrine hidradenitis associated with Hodgkin's disease and chemotherapy: a case report. Arch Dermatol 1986; 122:809-11.
85. Scallan PJ, Kettler AH, Levy ML, Tschen JA. Neutrophilic eccrine hidradenitis: evidence implicating bleomycin as a causative agent. Cancer 1988; 62:2532-6.
86. Altaykan A, Boztepe G, Erkin G et al. Acute generalized exanthematous pustulosis induced by bleomycin and confirmed by patch testing. J Dermatol Treat 2004; 15:231-4.
87. Umebayashi Y, Enomoto H, Ogasawara M. Drug eruption due to peplomycin: an unusual form of Stevens-Johnson syndrome with pustules. J Dermatol 2004; 31:802-5.
88. Philpott MP, Sanders D, Westgate GE, Kealey T. Human hair growth in vitro: a model for the study of hair follicle biology. J Dermatol Sci 1994; 7:S55-72.
89. Soma T, Ogo M, Suzuki J et al. Analysis of apoptotic cell death in human hair follicles in vivo and in vitro. J Invest Dermatol 1998; 111:948-54.
90. Shetty MR. Case of pigmented banding of the nail caused by bleomycin. Cancer Treat Rep 1977; 61:501-2.
91. Gonzalez FU, Gil MCC, Martinez AA et al. Cutaneous toxicity of intralesional bleomycin administration in the treatment of periungual warts. Arch Dermatol 1986; 122:974-5.
92. Willer RAW. Nail dystrophy following intralesional injections of bleomycin for a periungual wart. Arch Dermatol 1984; 120:963-4.
93. Tager AM, Luster AD, Leary CP et al. Accessory cells with immunophenotypic and functional features of monocyte-derived dendritic cells are recruited to the lung during pulmonary inflammation. J Leukoc Biol 1999; 66:901-8.
94. Denholm EM, Rollins SM. Expression and secretion of transforming growth factor-b by bleomycin-stimulated rat alveolar macrophages. Am J Physiol 1993; 264:L36-42.
95. Denholm EM, Phan SH. The effects of bleomycin on alveolar macrophage growth factor secretion. Am J Pathol 1989; 134:355-63.
96. Kovacs EJ, Kelley J. Secretion of macrophage-derived growth factor during acute lung injury by bleomycin. J Leukoc Biol 1985; 37:1-14.
97. Yamamoto T, Katayama I, Nishioka K. Fibroblast proliferation by bleomycin stimulated peripheral blood mononuclear cell factors. J Rheumatol 1999; 26:609-15.
98. Ortiz LA, Moroz K, Liu JY et al. Alveolar macrophage apoptosis and TNF-alpha, but not p53, expression correlate with murine response to bleomycin. Am J Physiol 1998; 275:L1208-18.
99. Clark JC, Starcher BC, Uitto J. Bleomycin-induced synthesis of type I procollagen by human lung skin fibroblasts in culture. Biochim Biophys Acta 1980; 631:359-70.
100. Yamamoto T, Eckes B, Krieg T. Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin gene expression in human skin fibroblasts. Arch Dermatol Res 2000; 292:556-61.
101. Sterling KM Jr, DiPetrillo TA, Kotch JP, Cutroneo KR. Bleomycin-induced increase of collagen turnover in IMR-90 fibroblasts: an in vitro model of connective tissue restructuring during lung fibrosis. Cancer Res 1982; 42:3502-6.
102. Sato E, Koyama S, Robbins RA. Bleomycin stimulates lung fibroblast and epithelial cell lines to release eosinophil chemotactic activity. Eur Respir J 2000; 16:951-8.
103. Dirix LY, Libura M, Libura J et al. In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs 1997; 8:859-68.
104. Ishii H, Takada K. Bleomycin induces E-selectin expression in cultured umbilical vein endothelial cells by increasing its mRNA levels through activation of NF-κB/Rel. Toxicol Appl Pharmacol 2002; 184:88-97.
105. Phan SH, Gharaee-Kermani M, Wolber F, Ryan US. Stimulation of rat endothelial cell transforming growth factor-β production by bleomycin. J Clin Invest 1991; 87:148-54.
106. Cloos J, Reid CBA, van der Sterre MLT et al. A comparison of bleomycin-induced damage in lymphocytes and primary oral fibroblasts and keratinocytes in 30 subjects. Mutagenesis 1999; 14:87-93.
107. Lewis DA, Hurwitz SA, Spandau DF. UVB-induced apoptosis in normal human keratinocytes: role of the erbB receptor family. Exp Cell Res 2003; 284:316-27.
108. Thrall BD, Raha GA, Springer DL, Meadows GG. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs. Pigment Cell Res 1991; 4:234-9.